Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
AngloGold Ashanti Adds 6% On Decision To Invest $$$ In G2 Goldfields
-
Jim Cramer Calls $BTC ‘A Strange Animal’, Says ‘I Would Sell My Bitcoin Right Into This Rally’
-
J.B. Hunt Falls On Lower Profit In Q3, Below Street View
-
Bitcoin, ETH, XRP, ADA Get Stuck In Tight Ranges As Investors Attune To The Jackson Hole Symposium
-
El-Salvador Ignores IMF, Set to Open Second 'Bitcoin Embassy' in the US